Biognosys showcases proteomics innovations at HUPO World Congress
At this year’s Human Proteome Organization (HUPO) World Congress in Dresden, proteomics specialist Biognosys unveiled significant developments in protein analysis technology, with particular emphasis on their novel P2 Plasma Enrichment System.
The company’s proprietary P2 technology represents a notable advancement in plasma proteome analysis, achieving quantification of up to 7,000 proteins in human plasma samples when deployed on the Bruker timsTOF HT platform. For more focused research requiring deeper biological profiling, an alternative workflow can identify up to 9,000 proteins, albeit at lower throughput.
The technical innovation lies in the system’s single-well, single particle-type workflow, incorporating specialised surface chemistry with a novel buffer system. This combination effectively stabilises the protein corona that forms around particles in blood plasma. Notably, the system achieves a tenfold enrichment factor compared to untreated plasma when utilising the 4D dia-PASEF method and Spectronaut 19 data processing.
Comprehensive protein analysis solutions
Biognosys has positioned its offering to span both mass spectrometry-based and affinity-based approaches. The company now provides NULISAseq multiplex panels specifically designed for CNS disease and inflammation studies, complementing their established mass spectrometry services.
“Our P2 Plasma Enrichment System represents a significant leap forward in plasma proteomics, enabling researchers to achieve highest coverage at a throughput that until now was only achievable with affinity-based methods. As a label-free method it is also more economic and can now be deployed for large cohort studies,” said Oliver Rinner, PhD, CEO and Founder of Biognosys.
Alongside hardware innovations, Biognosys announced significant updates to their analytical software suite. Their Spectronaut 19 platform now incorporates enhanced capabilities for large-scale analysis of dia-PASEF data and proteome-wide turnover rate determination. The company also launched SpectroDive 12, featuring artificial intelligence-generated panels and improved quantification capabilities. “SpectroDive 12 sets a new benchmark for targeted proteomics workflows. With its advanced features for in-silico panel development and enhanced sensitivity, it empowers researchers to achieve more precise and comprehensive protein quantification, ultimately accelerating the pace of proteomics research,” commented Lukas Reiter, PhD, Chief Technology Officer at Biognosys.
Advances in drug development applications
The congress also saw Biognosys showcase developments in their TrueTarget platform, which utilises limited proteolysis mass spectrometry (LiP-MS) for drug target identification and validation. The platform now features automated sample preparation integrated with short-gradient LC-MS, making it suitable for higher-throughput drug screening applications. The system employs machine learning-based scoring to predict potential drug binding sites at the peptide level, supporting both target-based and phenotypic drug discovery approaches.
These developments collectively represent significant progress in proteomics technology, potentially enabling more comprehensive protein studies across both research and clinical applications. The combination of enhanced plasma proteome analysis capabilities with sophisticated software tools may particularly benefit research into protein biomarkers and drug development programmes.
